5-HTTLPR polymorphism of serotonin transporter and effects of sertraline in terminally ill cancer patients: Report of eleven cases

Tumori

Volumn 94, Issue 4, 2008, Pages 563-567

  Schillani, Giulia ^a   Capozzo, Maria Anna ^a   Aguglia, Eugenio ^a   De Vanna, Maurizio ^a   Grassi, Luigi ^b   Conte, Maria Anna ^c   Giraldi, Tullio ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c ASL1   (Italy)

Author keywords

Antidepressant drugs; Mental adaptation to cancer; Palliative care; Pharmacogenetics

Indexed keywords

SEROTONIN TRANSPORTER; SERTRALINE;

ADAPTIVE BEHAVIOR; ADVANCED CANCER; ALLELE; ANXIETY; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAMILTON SCALE; HOSPITAL ADMISSION; HUMAN; MALE; TERMINALLY ILL PATIENT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 54749143573     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160809400419     Document Type: Article

References (27)

1. Breitbart W, Jaramillo JR, Chochinov HM: Palliative and terminal care. In: Psycho-Oncology, Holland JC (Ed), pp 437-449, Oxford University Press, New York, 1998.
2. Breitbart W, Payne DK: Pain. In: Psycho-Oncology, Holland JC (Ed), pp 450-467, Oxford University Press, New York, 1998.
3. Williams S, Dale J: The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer, 94: 372-390, 2006.
4. Miller KE, Adams SM, Miller MM: Antidepressant medication use in palliative care. Am J Hosp Palliat Care, 23: 127-133, 2006.
5. Grassi L, Rosti G, Albieri G, Marangolo M: Depression and abnormal illness behavior in cancer patients, Gen Hosp Psychiatry, 11: 404-411, 1989.
6. Block SD: Assessing and managing depression in the terminally ill patients. Ann Intern Med, 132: 209-218, 2000.
7. Akechi T, Okuyama T, Sugawara Y, Nakano T, Shima Y, Uchitomi Y: Major depression, adjustment disorders, and post-traumatic stress disorders in terminally ill cancer patients: associated and predictive factors. J Clin Oncol, 22; 1957-1965, 2004.
8. Lloyd-Williams M: Difficulties in diagnosing and treating depression in the terminally ill cancer patient. Postgrad Med J, 76; 555-558, 2000.
9. Pessin H, Olden M, Jacobson C, Kosinski A: Clinical assessment of depression in terminally ill cancer patients: a pratical guide. Palliat Support Care, 3: 319-324, 2005.
10. Kraft JB, Peters EJ, Slager SL, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP: Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry, 61: 734-742, 2007.
11. Serretti A, Artioli P: The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics J, 4: 233-244, 2004.
12. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science, 274: 1527-1531, 1996.
13. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ: Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry, 10: 1115-1119, 2002.
14. Perlis RH, Mischoulon D, Smoller JW, Wan YJ, Lamon-Fava S, Lin KM, Rosenbaum JF, Fava M: Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry, 54: 879-883, 2003.
15. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L: 5-HT-TLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with Citalopram in a 12-weeks follow up study. J Clin Psychopharmacol, 23: 563-567, 2003.
16. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB: The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl.), 17: 525-529, 2004.
17. Serretti A, Mandelli L, Lorenzi C, Pirovano A, Olgiati P, Colombo C, Smeraldi E: Serotonin transporter gene influences the time course of improvement of "core" depressive and somatic anxiety symptoms during treatment with SS-RIs for recurrent mood disorders. Psychiatry Res, 149: 185-193, 2007.
18. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand, 67: 361-370, 1983.
19. Watson M, Law M, Dos Santos M, Greer S, Baruch J, Bliss J: The Mini-Mac: further development of the Mental Adjustment to Cancer scale. J Psychosoc Oncol, 12: 33-46, 1994.
20. Gelernter J, Kranzler H, Cubells JF: Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects. Hum Genet, 101: 243-246, 1997.
21. Butler LD, Koopman C, Cordova MJ, Garlan RW, DiMiceli S, Spiegel D: Psychological distress and pain significantly increase before death in metastatic breast cancer patients. Psychosom Med, 65: 416-426, 2003.
22. Bukberg J, Penman D, Holland JC: Depression in hospitalized cancer patients. Psychosom Med, 46: 199-212, 1984.
23. Faller H, Schmidt M: Prognostic value of depressive coping and depression in survival of lung cancer patients. Psychooncology, 13: 359-363, 2004.
24. Collie K, Wong P, Tilston J, Butler LD, Turner-Cobb J, Kreshka MA, Parsons R, Graddy K, Cheasty JD, Koopman C: Self-efficacy, coping, and difficulties interacting with health care professionals among women living with breast cancer in rural communities. Psychooncology, 14: 901-912, 2005.
25. Grassi L, Biancosino B, Marmai L, Righi R: Effect of reboxetine on major depressive disorder in breast cancer patients: an open label study. J Clin Psychiatry, 65: 515-520, 2004.
26. Chochinov HM: Dying, dignity, and new horizons in palliative end-of-life care. CA Cancer J Clin, 56: 84-103, 2006.
27. Dein S: Psychiatric liaison in palliative care. Advances in Psychiatric Treatment, 9: 241-248, 2003.